JPWO2006009179A1 - 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 - Google Patents
水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 Download PDFInfo
- Publication number
- JPWO2006009179A1 JPWO2006009179A1 JP2006529251A JP2006529251A JPWO2006009179A1 JP WO2006009179 A1 JPWO2006009179 A1 JP WO2006009179A1 JP 2006529251 A JP2006529251 A JP 2006529251A JP 2006529251 A JP2006529251 A JP 2006529251A JP WO2006009179 A1 JPWO2006009179 A1 JP WO2006009179A1
- Authority
- JP
- Japan
- Prior art keywords
- water
- adsorbent
- fine particles
- adsorber
- insoluble fine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000010419 fine particle Substances 0.000 title claims abstract description 144
- 239000003463 adsorbent Substances 0.000 title claims abstract description 116
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000008081 blood perfusion Effects 0.000 title claims abstract description 33
- 239000002245 particle Substances 0.000 claims abstract description 69
- 238000009826 distribution Methods 0.000 claims abstract description 28
- 102000008946 Fibrinogen Human genes 0.000 claims description 8
- 108010049003 Fibrinogen Proteins 0.000 claims description 8
- 230000007717 exclusion Effects 0.000 claims description 8
- 229940012952 fibrinogen Drugs 0.000 claims description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 6
- 102000034238 globular proteins Human genes 0.000 claims description 6
- 108091005896 globular proteins Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 11
- 238000000576 coating method Methods 0.000 abstract description 7
- 239000011248 coating agent Substances 0.000 abstract description 6
- 238000005469 granulation Methods 0.000 abstract description 5
- 230000003179 granulation Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 description 46
- 239000007788 liquid Substances 0.000 description 35
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 28
- 230000001717 pathogenic effect Effects 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 16
- 230000004087 circulation Effects 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000002002 slurry Substances 0.000 description 16
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 14
- 239000001913 cellulose Substances 0.000 description 12
- 229920002678 cellulose Polymers 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 9
- 229960000633 dextran sulfate Drugs 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 7
- 229960004799 tryptophan Drugs 0.000 description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 4
- -1 xylan sulfate Chemical class 0.000 description 4
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000009141 biological interaction Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 125000003700 epoxy group Chemical group 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 238000011045 prefiltration Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- UDQCRUSSQAXPJY-VIFPVBQESA-N (2s)-2-amino-3-(1h-indol-3-yl)propan-1-ol Chemical compound C1=CC=C2C(C[C@@H](CO)N)=CNC2=C1 UDQCRUSSQAXPJY-VIFPVBQESA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PZAGQUOSOTUKEC-UHFFFAOYSA-N acetic acid;sulfuric acid Chemical compound CC(O)=O.OS(O)(=O)=O PZAGQUOSOTUKEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N anethole Polymers COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- DABYEOZXRSTEGL-NSHDSACASA-N ethyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OCC)=CNC2=C1 DABYEOZXRSTEGL-NSHDSACASA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- DABYEOZXRSTEGL-UHFFFAOYSA-N racemic tryptophan ethyl ester Natural products C1=CC=C2C(CC(N)C(=O)OCC)=CNC2=C1 DABYEOZXRSTEGL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Polymers COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/24—Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28004—Sorbent size or size distribution, e.g. particle size
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
その一つが鐘淵化学工業(株)のβ2ミクログロブリン(分子量:約12000)除去用の吸着器である。この吸着器に使用されている吸着材(非特許文献2を参照)は粒径が約500μmで粒径分布が均一なものである。用途は、関節痛を伴うアミロイド症に適用され、血液透析の際に利用される。吸着材の粒径分布が均一であるため水不溶性微粒子の除去装置(特許文献1を参照)などを用いた場合、吸着材をロスすることなく水不溶性微粒子を除去するのが容易である。つまり水不溶性微粒子への対策の一つとして粒径分布が均一な吸着材を用いている。但し、粒径分布が均一な吸着材(特許文献2を参照)を製造するには特殊な造粒装置(特許文献3を参照)が必要である。また、吸着材の担体として適用できる均一な粒径分布をもつ汎用水不溶性担体は市販品として存在しないのが実状である。
2 水不溶性微粒子
3 水不溶性微粒子を除去するメッシュ
4 フィルター
5 ポンプ
6 ノズル
7 微粒子除去槽
8 血液の流入口
9 血液の流出口
10 カラム
11 吸着器
12 吸着器のメッシュ
この水不溶性微粒子を除去するメッシュ目開きサイズは、小さすぎると水不溶性微粒子を除去することができなくなり、大きすぎると水不溶性微粒子除去の際に吸着材がメッシュから流出してロスが生じてしまう。更に、メッシュから流出した吸着材の量が多いと水不溶性微粒子を除去するフィルターの目詰まりが生じてしまい連続的な処理が困難となる。水不溶性微粒子を除去するメッシュ目開きサイズは、吸着器のメッシュ目開きサイズに対する水不溶性微粒子を除去するメッシュ目開きサイズの比は1.3以上、1.5以下となるサイズが好ましい。
両端に孔径15μmのフィルターを装着したガラス製円筒カラム(内径9mm、カラム長150mm)にアガロース材料(バイオラッド(Bio−rad)社製のBiogelA−5m、粒径50〜100メッシュ)、ビニル系高分子材料(東ソー(株)製のトヨパールHW−65、粒径50〜100μm)およびセルロース材料(チッソ(株)製のセルロファインGC−700m、粒径45〜105μm)をそれぞれ均一に充填し、ペリスタティックポンプにより水を流し、流量と圧力損失ΔPとの関係を求めた。その結果を図3に示す。
平均粒径約446μm、粒径分布の変動係数14%、球状蛋白質の排除限界分子量が5×107の多孔質セルロースビーズ24L、4N NaOH水溶液6.6Lおよびエピクロロヒドリン7Lを加え、水を加えて全量33Lとし、40℃で2時間攪拌して反応させた。反応後ビーズを水で十分洗浄してエポキシ化セルロースビーズを得た。エポキシ化セルロースビーズのエポキシ基量は16.4μmol/mL(湿潤体積)であった。
製造例の吸着材を、両端に目開き150μmのポリエチレンテレフタレート製メッシュを装着した内径10mm、長さ34mmのアクリル製カラム(容積2.7mL)に充填し、吸着器を得た。次に、血液1mLに対し5単位のヘパリンを添加し抗凝固した健常人血液40mLを、流速6.5mL/minで2時間循環させた。2時間循環前後のプール血液の血球数は表1に示す通りであり、いずれの血球も良好な通過性を示した。また循環前後のプール血液中のLDL−コレステロール、フィブリノーゲン、およびHDL−コレステロールの濃度は表2に示す通りであり、LDL−コレステロールが163mg/dLから105mg/dLに、フィブリノーゲンが210mg/dLから152mg/dLに低下したが、HDL−コレステロールは49mg/dLから46mg/dLへ低下するに留まった。
212μmの目開きのメッシュを設けた槽内に製造例の吸着材(スラリー濃度30%、液量16L)を分散させ、メッシュで区切られた吸着材の入っていない箇所よりスラリー溶媒液(水)を循環ラインを用いて、ノズルを経て槽内にスラリー溶媒液を再注入し、槽内の吸着材を常時分散させながら、スラリー溶媒液の循環を流量32L/minで10分間行った。また、メッシュを設けた槽外にあるスラリー溶媒液の循環ラインには、目開き104μmのメッシュを設けおり、上記10分間の循環中に目開き212μmのメッシュから流出して目開き104μmのメッシュに捕捉された吸着材の量を求めた。その量は表3の通り8.0mLであった。
233μmの目開きのメッシュを設けた槽内に製造例の吸着材(スラリー濃度30%、液量16L)を分散させ、メッシュで区切られた吸着材の入っていない箇所よりスラリー溶媒液(水)を循環ラインを用いて、ノズルを経て槽内にスラリー溶媒液を再注入し、槽内の吸着材を常時分散させながら、スラリー溶媒液の循環を流量32L/minで10分間行った。また、メッシュを設けた槽外にあるスラリー溶媒液の循環ラインには、目開き104μmのメッシュを設けおり、上記10分間の循環中に目開き233μmのメッシュから流出して目開き104μmのメッシュに捕捉された吸着材の量を求めた。その量は表3の通り20mLであった。
なお、吸着器のメッシュ目開きを実施例1と同じサイズを採用して、水不溶性微粒子の除去槽のメッシュ目開きを本例と同じサイズを利用した場合、水不溶性微粒子を除去するメッシュ目開きサイズ(233μm)に対する吸着器のメッシュ目開きサイズ(150μm)の比は1.55である。
212μmの目開きのメッシュを設けた微粒子除去槽内の洗浄液に製造例の吸着材(スラリー濃度15%、液量16L)を分散させ、メッシュで区切られた吸着材の入っていない箇所より、212μmのメッシュから流出した水不溶性微粒子を捕捉する0.22μmのフィルターを有する循環・水不溶性微粒子除去ラインを用いて、洗浄液中の水不溶性微粒子をフィルターによって捕捉させながら洗浄液を流量32L/minで循環し、微粒子除去槽内に洗浄液をノズルを経て再注入し、微粒子除去槽内の吸着材を常時分散させ、水不溶性微粒子の除去を10分間行った。なお、水不溶性微粒子を除去するメッシュ目開きサイズ(212μm)に対する吸着器のメッシュ目開きサイズ(150μm)の比は1.41である。
212μmの目開きのメッシュを設けた微粒子除去槽内の洗浄液に製造例の吸着材(スラリー濃度30%、液量16L)を分散させ、メッシュで区切られた吸着材の入っていない箇所より、212μmのメッシュから流出した水不溶性微粒子を捕捉する0.22μmのフィルターを有する循環・水不溶性微粒子除去ラインを用いて、洗浄液中の水不溶性微粒子をフィルターによって捕捉させながら洗浄液を流量32L/minで循環し、微粒子除去槽内に洗浄液をノズルを経て再注入し、微粒子除去槽内の吸着材を常時分散させ、水不溶性微粒子の除去を10分間行った。なお、水不溶性微粒子を除去するメッシュ目開きサイズ(212μm)に対する吸着器のメッシュ目開きサイズ(150μm)の比は1.41である。
212μmの目開きのメッシュを設けた微粒子除去槽内の洗浄液に製造例の吸着材(スラリー濃度50%、液量16L)を分散させ、メッシュで区切られた吸着材の入っていない箇所より、212μmのメッシュから流出した水不溶性微粒子を捕捉する0.22μmのフィルターを有する循環・水不溶性微粒子除去ラインを用いて、洗浄液中の水不溶性微粒子をフィルターによって捕捉させながら洗浄液を流量32L/minで循環し、微粒子除去槽内に洗浄液をノズルを経て再注入し、微粒子除去槽内の吸着材を常時分散させ、水不溶性微粒子の除去を10分間行った。なお、水不溶性微粒子を除去するメッシュ目開きサイズ(212μm)に対する吸着器のメッシュ目開きサイズ(150μm)の比は1.41である。
180μmの目開きのメッシュを設けた微粒子除去槽内の洗浄液に製造例の吸着材(スラリー濃度30%、液量16L)を分散させ、メッシュで区切られた吸着材の入っていない箇所より、180μmのメッシュから流出した水不溶性微粒子を捕捉する0.22μmのフィルターを有する循環・水不溶性微粒子除去ラインを用いて、洗浄液中の水不溶性微粒子をフィルターによって捕捉させながら洗浄液を流量32L/minで循環し、微粒子除去槽内に洗浄液をノズルを経て再注入し、微粒子除去槽内の吸着材を常時分散させ、水不溶性微粒子の除去を10分間行った。なお、水不溶性微粒子を除去するメッシュ目開きサイズ(180μm)に対する吸着器のメッシュ目開きサイズ(150μm)の比は1.20である。
Claims (5)
- 個数基準の平均粒径が300μm以上、600μm以下で、粒径分布の変動係数が10%以上、20%以下の水不溶性担体の粒子群からなる吸着材が充填された直接血液灌流用吸着器であり、器内に存在する10μm以上の水不溶性微粒子数の測定値の平均+6SDが吸着器当たり24000個以下、25μm以上の水不溶性微粒子数の測定値の平均+6SDが吸着器当たり4000個以下である直接血液灌流用吸着器。
- 吸着材の球状蛋白質の排除限界分子量が2×104以上、1×108以下である請求項1記載の直接血液灌流用吸着器。
- 吸着材がセルロース系担体である請求項1又は2記載の直接血液灌流用吸着器。
- 吸着材がセルロース系担体で、吸着材の球状蛋白質の排除限界分子量が5×105以上、1×108以下で、且つ低密度リポ蛋白およびフィブリノーゲンの吸着材を充填した請求項1記載の直接血液灌流用吸着器。
- 吸着器のメッシュ目開きサイズに対する水不溶性微粒子を除去するメッシュ目開きサイズの比が1.3以上、1.5以下であるメッシュを用いて、個数基準の平均粒径が300μm以上、600μm以下で、且つ粒径分布の変動係数が10%以上、20%以下の粒子群からなる吸着材から水不溶性微粒子を除去して、直接血液灌流用吸着器に充填する吸着材を取得する方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006529251A JP4908216B2 (ja) | 2004-07-23 | 2005-07-20 | 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004215411 | 2004-07-23 | ||
JP2004215411 | 2004-07-23 | ||
PCT/JP2005/013328 WO2006009179A1 (ja) | 2004-07-23 | 2005-07-20 | 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 |
JP2006529251A JP4908216B2 (ja) | 2004-07-23 | 2005-07-20 | 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006009179A1 true JPWO2006009179A1 (ja) | 2008-05-01 |
JP4908216B2 JP4908216B2 (ja) | 2012-04-04 |
Family
ID=35785286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006529251A Active JP4908216B2 (ja) | 2004-07-23 | 2005-07-20 | 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8272518B2 (ja) |
EP (1) | EP1790365B1 (ja) |
JP (1) | JP4908216B2 (ja) |
KR (1) | KR101236046B1 (ja) |
CN (1) | CN1988926B (ja) |
WO (1) | WO2006009179A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1621220B1 (en) * | 2003-05-08 | 2014-11-19 | Kaneka Corporation | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment |
BRPI0619820A2 (pt) | 2005-12-13 | 2011-10-18 | Exthera Ab | método de remoção extracorpórea de um micróbio patogênico, uma célula inflamatória ou uma proteìna inflamatória do sangue |
WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
JP5318586B2 (ja) * | 2009-01-08 | 2013-10-16 | 株式会社カネカ | 血液適合性に優れた免疫グロブリン吸着材、及び吸着器 |
US8758286B2 (en) * | 2009-12-01 | 2014-06-24 | Exthera Medical Corporation | Method for removing cytokines from blood with surface immobilized polysaccharides |
WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
US20130068691A1 (en) * | 2011-08-05 | 2013-03-21 | Henry John Smith | Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders |
DK2861273T3 (da) | 2012-06-13 | 2017-11-27 | Exthera Medical Corp | Anvendelse af heparin og kulhydrater til behandling af cancer. |
EP3013445B1 (en) | 2013-06-24 | 2019-11-06 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
JP6806563B2 (ja) | 2013-11-08 | 2021-01-06 | エクステラ・メディカル・コーポレーション | 吸着媒体を使用する感染症の診断法 |
MX2016007492A (es) | 2013-12-09 | 2017-03-06 | Univ Leland Stanford Junior | Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento. |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
BR112016024569B1 (pt) | 2014-04-24 | 2023-01-03 | Exthera Medical Corporation | Método ex vivo para remover bactérias de uma amostra retirada de um indivíduo que é suspeito de estar infectado com a mesma |
AU2015321601B2 (en) | 2014-09-22 | 2020-04-23 | Exthera Medical Corporation | Wearable hemoperfusion device |
JP6921006B2 (ja) | 2015-06-15 | 2021-08-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 老化関連症状を治療するための方法および組成物 |
EP3422943A4 (en) | 2016-03-02 | 2019-10-16 | ExThera Medical Corporation | METHOD OF TREATING DRUG ENTRIES |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
EP3492166A4 (en) * | 2016-08-01 | 2020-03-11 | Kaneka Corporation | ADSORPTION AGENT FOR CALCIPROTE PARTICLES, ADSORPTION REMOVAL SYSTEM AND METHOD FOR USE THEREOF |
US20200215253A1 (en) * | 2017-09-08 | 2020-07-09 | Toray Industries, Inc. | Immunosuppressive leukocyte adsorption material and adsorption column |
WO2019084111A1 (en) * | 2017-10-24 | 2019-05-02 | DD Innovations Lab, LLC | APPARATUS AND METHODS FOR REMOVING TOXINS FROM BLOOD BY PLASMASPHERESIS |
TWI724396B (zh) * | 2018-03-30 | 2021-04-11 | 日商旭化成醫療股份有限公司 | 血液淨化器及其製法 |
CN108732114B (zh) * | 2018-04-11 | 2021-01-05 | 武汉瑞法医疗器械有限公司 | 快速检测血脂吸附剂中硫酸葡聚糖固定量的方法 |
JP2021041378A (ja) * | 2019-09-13 | 2021-03-18 | 旭化成株式会社 | 多孔性成形体 |
CN112473628A (zh) * | 2020-11-05 | 2021-03-12 | 西安交通大学医学院第一附属医院 | 血液净化吸附剂及其制备方法和血液灌流器 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5743747A (en) * | 1980-08-29 | 1982-03-11 | Terumo Corp | Manufacture of artificial internal organ |
JPS62191033A (ja) * | 1986-02-06 | 1987-08-21 | Kanegafuchi Chem Ind Co Ltd | 均一液滴の形成方法 |
JPH01275601A (ja) * | 1988-04-27 | 1989-11-06 | Kanegafuchi Chem Ind Co Ltd | セルロース系粒子 |
JPH04145941A (ja) * | 1990-10-05 | 1992-05-19 | Kanegafuchi Chem Ind Co Ltd | 医療用吸着材の微粒子除去方法および装置 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4171283A (en) * | 1976-08-04 | 1979-10-16 | Kuraray Co., Ltd. | Hemoperfusion adsorbents |
US4358376A (en) * | 1979-10-29 | 1982-11-09 | Terumo Corporation | Apparatus for detoxifying body fluid |
JPS5662540A (en) | 1979-10-29 | 1981-05-28 | Terumo Corp | Washing method of active carbon for purifying body fluid |
US4694044A (en) * | 1984-03-09 | 1987-09-15 | Research Development Corp. Of Japan | Adsorbent |
NZ213819A (en) * | 1984-10-31 | 1988-05-30 | Kanegafuchi Chemical Ind | Lipoprotein adsorbent using hydroxy-containing polymer gel |
JP3285441B2 (ja) | 1993-11-17 | 2002-05-27 | 旭メディカル株式会社 | 血管閉塞性疾患血漿の血漿粘度低下用吸着材及び血漿粘度低下装置 |
CN1130089A (zh) * | 1995-02-28 | 1996-09-04 | 黄宁 | 微型血液净化器 |
TW514537B (en) * | 1997-03-25 | 2002-12-21 | Kanegafuchi Chemical Ind | Adsorbent for removing hepatitis c virus and adsorption apparatus |
JP4156160B2 (ja) | 2000-01-25 | 2008-09-24 | 株式会社カネカ | 直接血液灌流用体液処理器 |
CN1220531C (zh) * | 2001-01-30 | 2005-09-28 | 钟渊化学工业株式会社 | 能够直接进行血液灌流的体液处理器 |
CN1408442A (zh) * | 2002-09-09 | 2003-04-09 | 天津医科大学总医院 | 全血灌流吸附治疗用吸附剂 |
-
2005
- 2005-07-20 EP EP05766271.0A patent/EP1790365B1/en active Active
- 2005-07-20 JP JP2006529251A patent/JP4908216B2/ja active Active
- 2005-07-20 KR KR1020077002739A patent/KR101236046B1/ko active IP Right Grant
- 2005-07-20 US US11/572,542 patent/US8272518B2/en active Active
- 2005-07-20 WO PCT/JP2005/013328 patent/WO2006009179A1/ja active Application Filing
- 2005-07-20 CN CN2005800248877A patent/CN1988926B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5743747A (en) * | 1980-08-29 | 1982-03-11 | Terumo Corp | Manufacture of artificial internal organ |
JPS62191033A (ja) * | 1986-02-06 | 1987-08-21 | Kanegafuchi Chem Ind Co Ltd | 均一液滴の形成方法 |
JPH01275601A (ja) * | 1988-04-27 | 1989-11-06 | Kanegafuchi Chem Ind Co Ltd | セルロース系粒子 |
JPH04145941A (ja) * | 1990-10-05 | 1992-05-19 | Kanegafuchi Chem Ind Co Ltd | 医療用吸着材の微粒子除去方法および装置 |
Also Published As
Publication number | Publication date |
---|---|
WO2006009179A1 (ja) | 2006-01-26 |
KR20070035593A (ko) | 2007-03-30 |
KR101236046B1 (ko) | 2013-02-21 |
US20080314817A1 (en) | 2008-12-25 |
US8272518B2 (en) | 2012-09-25 |
CN1988926A (zh) | 2007-06-27 |
CN1988926B (zh) | 2010-05-05 |
EP1790365A4 (en) | 2010-11-03 |
JP4908216B2 (ja) | 2012-04-04 |
EP1790365B1 (en) | 2015-11-18 |
EP1790365A1 (en) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4908216B2 (ja) | 水不溶性微粒子を除去した吸着材を充填した直接血液灌流用吸着器、および水不溶性微粒子を除去した直接血液灌流用吸着材の取得方法 | |
JP4138488B2 (ja) | 直接血液灌流が可能な体液処理器 | |
JP4578405B2 (ja) | 全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器 | |
US6878269B2 (en) | Device for body fluid purification and system for body fluid purification | |
CA2216718C (en) | Adsorbent for disease-related factors in body fluids, method of elimination by adsorption, body fluid purifier, and apparatus for purifying body fluids | |
JPS62192172A (ja) | 吸着体 | |
JPS59169532A (ja) | C反応性蛋白の吸着材 | |
JP3157026B2 (ja) | 血液浄化用吸着材 | |
JP2008206753A (ja) | 炎症性疾患処置カラム | |
JP4156160B2 (ja) | 直接血液灌流用体液処理器 | |
JPS6256782B2 (ja) | ||
JP4141224B2 (ja) | 低密度リポ蛋白およびフィブリノーゲンの吸着材、及びその吸着器 | |
JP4837221B2 (ja) | 強心配糖体の吸着材、吸着除去方法および吸着器 | |
JPS59156431A (ja) | 吸着体 | |
JPH01145071A (ja) | リポ蛋白を除去した血漿の製造方法 | |
JPS5922557A (ja) | エンドトキシン血症治療器 | |
JPH088928B2 (ja) | 低比重リポ蛋白質を除去した血漿を製造する装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110613 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110613 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111220 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120112 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150120 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4908216 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150120 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |